about
Surveillance after cardiac arrest in patients with Brugada syndrome without an implantable defibrillator: An alarm effect of the previous syncope.Influence of meteorological conditions on hospital admission in patients with acute coronary syndrome with and without ST-segment elevation: Results of the AIRACOS study.Change in growth differentiation factor 15, but not C-reactive protein, independently predicts major cardiac events in patients with non-ST elevation acute coronary syndrome.Vascular approaches for transcatheter aortic valve implantation.The role of neopterin in atherogenesis and cardiovascular risk assessment.Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromesNeopterin for risk assessment in angina pectoris.2014 annual summary and new projects in Revista Española de Cardiología.Beta-Blockers and Calcium Channel Blockers: First Line Agents.Elevated circulating soluble form of CD40 ligand in patients with cardiac syndrome X.Short-term effects of air pollution, markers of endothelial activation, and coagulation to predict major adverse cardiovascular events in patients with acute coronary syndrome: insights from AIRACOS study.A comparative study of markers of inflammation for the assessment of cardiovascular risk in patients presenting to the emergency department with acute chest pain suggestive of acute coronary syndrome.C-reactive protein elevation and disease activity in patients with coronary artery disease.Effect of Serum Growth Differentiation Factor-15 and the Syntax Score on 2-Year Outcomes in Patients With Acute Coronary Syndrome.Transcatheter aortic valve implantation in very elderly patients: immediate results and medium term follow-up.Usefulness of intraplatelet melatonin levels to predict angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.Low frequency of embolic protection devices in saphenous vein intervention: a matter of lack of conviction?Global left ventricular longitudinal strain is associated with decreased melatonin levels in patients with acute myocardial infarction: a two-dimensional speckle tracking study.Will TAVI Be the Standard of Care in the Treatment of Aortic Stenosis?Relation of growth-differentiation factor 15 to left ventricular remodeling in ST-segment elevation myocardial infarction.[Joint evolution of cardiovascular imaging techniques and their publications].Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease.Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia.Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris.Fatal retroperitoneal haemorrhage associated with enoxaparin and impaired renal function.Real incidence of diabetes mellitus in a coronary disease population.The Year 2011 in Interventional Cardiology.Dual antiplatelet treatment after coronary artery bypass surgery.Intracoronary abciximab and local anti-inflammatory effects.Percutaneous implantation of the CoreValve® self-expanding valve prosthesis in patients with severe aortic stenosis and porcelain aorta: medium-term follow-up.Extracorporeal membrane oxygenation system as a bridge to reparative surgery in ventricular septal defect complicating acute inferoposterior myocardial infarction.Rationale and design of a multicentre, prospective, randomised, controlled clinical trial to evaluate the efficacy of the adipose graft transposition procedure in patients with a myocardial scar: the AGTP II trial.Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing.Neutrophil count and infarct size in patients with acute myocardial infarction.The Prevalence of Patient-Prosthesis Mismatch Can Be Reduced Using the Trifecta Aortic Prosthesis.Serum ferritin deficiency and major adverse cardiovascular events after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction without anemia.Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations.Magda Heras i Fortuny, an indelible imprint on Revista Española de Cardiología.Comments on the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease.Screening of the Filamin C Gene in a Large Cohort of Hypertrophic Cardiomyopathy Patients.
P50
Q33167228-B47BC547-EFEE-4499-876B-A3DD1B6BB19FQ33465668-B078F78B-7AD2-499E-B4CE-B4F028F6D980Q33563146-B59F1B2F-42D8-4FEE-95E4-CD33230E73C0Q33774013-83FEB06E-A79F-457F-88F6-D539F8646545Q34020110-46660FA8-8AFF-4AB2-9D75-A5964B52B404Q35582637-B4AA3B37-8306-4B78-8C23-40734BC4635EQ37523320-93006541-2426-4190-BD0E-E542D5F72483Q38365632-0D944C44-0B40-4D85-B56A-0385B04BBC41Q38941375-CE34080A-E1A4-4958-8622-6A3214A7F66EQ39823529-F4F8792B-BD04-4C22-98B3-95962EA82D39Q39893052-EDBB6FC5-E4EC-4436-AEDC-5A2559C4E6DFQ40402294-C72D9797-B45E-4CFB-B0C2-1CCD6D1EFA9EQ40523511-5A13397C-FFCB-49CF-8A42-70A2CE828D51Q40834034-C71C51B7-D9A3-4C36-A029-DFC5CBD3ABFFQ41791006-03474AF4-8708-4FB7-8F7A-3DE84A2E0437Q42795743-E48F83E1-4A8B-4CB3-BA1D-F8C5FEFE7BA0Q43428556-CEC70856-A1BC-4C59-A84B-864B5FC2B100Q43476431-B5C8F0DE-9D6C-4C0C-B920-7C81FFDBFFF4Q43944437-6B4B4291-DF19-467E-A339-6E7A0626AD12Q43983466-0DA2CB9E-B3E9-4CDF-98AB-00FEE6C5ADD0Q44108003-768C4315-8173-422F-84D7-8043343A96ADQ44783800-F48E6082-0293-4FCF-AA11-21A351170CB1Q44987365-338A308B-FFB0-4A81-B51D-16F1E25752F5Q45069609-7457422A-84F3-46CF-8D14-F1B17F72BFA3Q45262933-64874327-CFAB-48BC-B427-D3F8A0AD18E4Q45349643-055206EA-DD42-4DBD-9EEA-9F637C4153E4Q45897942-36C8A237-681B-45E2-9AC8-EB2BD11F7756Q46395782-F790B4A3-F995-4301-8731-8083DFCD7E00Q46791798-8263F262-DEAB-47E3-9DAF-C16BE125A389Q46973241-37C7C95B-19EC-4592-A21B-10B62C1E0FA6Q47107269-74BDCF3E-9ACE-496B-9DC7-0353C723C254Q47155864-A6176B9B-8438-45FE-97A4-4D6E54D3D2F9Q47198055-885B4570-3A2A-443F-9FFD-BD1B00753F8FQ47409029-6B23B1ED-56AC-4368-BFA9-75B251FBAE7AQ47614925-E5768EDE-74BC-46D2-88FA-3BEFA2CF77D5Q47880862-DDD0BB78-6D41-4CCE-BAF2-71BEBD0CA005Q47978396-C98BE9C4-667E-4F30-B0A5-16AFCACA08B3Q48060112-68CF3939-1D7E-457E-A85C-B1E9DC7EE727Q49581357-1CDB3FEB-CEB3-458C-9785-D18F5900BDF2Q50212252-ADE77B15-ECB3-4CB3-B0C4-DDA5D5A32862
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Pablo Avanzas
@ast
Pablo Avanzas
@en
Pablo Avanzas
@es
Pablo Avanzas
@nl
Pablo Avanzas
@sl
type
label
Pablo Avanzas
@ast
Pablo Avanzas
@en
Pablo Avanzas
@es
Pablo Avanzas
@nl
Pablo Avanzas
@sl
prefLabel
Pablo Avanzas
@ast
Pablo Avanzas
@en
Pablo Avanzas
@es
Pablo Avanzas
@nl
Pablo Avanzas
@sl
P214
P1053
B-6811-2008
P106
P21
P214
P31
P3829
P496
0000-0002-4958-6108
P735
P7859
lccn-n2014183903